Difference between revisions of "Team:CSU CHINA"

Line 3: Line 3:
  
 
<h1> We are CSU_CHINA! </h1>
 
<h1> We are CSU_CHINA! </h1>
<img src="https://static.igem.org/mediawiki/2018/thumb/b/b2/T--CSU_CHINA--TeamLogo.png/320px-T--CSU_CHINA--TeamLogo.png">
 
 
  
 
<div class="column full_size" >
 
<div class="column full_size" >
 
<p>Let's do this! </p>
 
 
 
<img src="https://static.igem.org/mediawiki/2018/9/94/T--CSU_CHINA--labimage.jpeg">
 
 
  
 
</div>  
 
</div>  
Line 18: Line 10:
 
<div class="column half_size" >  
 
<div class="column half_size" >  
 
<div class="highlight">
 
<div class="highlight">
 +
<img src="https://static.igem.org/mediawiki/2018/2/22/T--CSU_CHINA--intro1.png">
 
<h1>Description </h1>  
 
<h1>Description </h1>  
 
<p>
 
<p>
  The suprachiasmatic nucleus (SCN) controls the circadian rhythm of physiological and behavioural processes in mammals. Prokineticin 2 (PK2), a cysteine-rich secreted protein, functions as an output molecule from the SCN circadian clock. PK2 messenger RNA is rhythmically expressed in the SCN, and the phase of PK2 rhythm is responsive to light entrainment. Molecular and genetic studies have revealed that PK2 is a gene that is controlled by a circadian clock (clock-controlled).  
+
-Liver cancer is cancer that begins in the cells of your liver. By the end of 2017, the incidence rate of liver cancer in China ranks the third in the world, and the mortality rate is the second. At present, the treatment methods of liver cancer include surgical resection, liver transplantation, local ablation, interventional therapy, radiotherapy, targeted therapy, immunotherapy and so forth.
 +
-Our project is to design a series of genetic circuits which specifically kill tumors, whose main components includes liver cancer cell cell-specific promoter, microRNA binding domain, GAL - 4 and GAL-80, thymidine kinase (TK) for gene therapy , etc.
 +
-The main principle of this loop is as follows: In liver cancer cells, there is a specific promoter that can activate the transcription and expression of GAL-4, so that a small dose of GAL-4 can bind to the upstream of the gene expressing TK, thereby triggering TK kinase to achieve tumor killing effect by gene therapy. And due to the lack of this specific promoter in normal cells, GAL-80 also has a normal inhibitory effect on GAL-4, so the loop is in an overall suppressed state.
 
</p>
 
</p>
  
Line 27: Line 22:
 
</p>
 
</p>
  
<img src="https://static.igem.org/mediawiki/2018/2/22/T--CSU_CHINA--intro1.png">
+
 
<img src="https://static.igem.org/mediawiki/2018/a/af/T--CSU_CHINA--intro2.png">
+
 
  
 
</div>
 
</div>

Revision as of 06:16, 28 July 2018


We are CSU_CHINA!

Description

-Liver cancer is cancer that begins in the cells of your liver. By the end of 2017, the incidence rate of liver cancer in China ranks the third in the world, and the mortality rate is the second. At present, the treatment methods of liver cancer include surgical resection, liver transplantation, local ablation, interventional therapy, radiotherapy, targeted therapy, immunotherapy and so forth. -Our project is to design a series of genetic circuits which specifically kill tumors, whose main components includes liver cancer cell cell-specific promoter, microRNA binding domain, GAL - 4 and GAL-80, thymidine kinase (TK) for gene therapy , etc. -The main principle of this loop is as follows: In liver cancer cells, there is a specific promoter that can activate the transcription and expression of GAL-4, so that a small dose of GAL-4 can bind to the upstream of the gene expressing TK, thereby triggering TK kinase to achieve tumor killing effect by gene therapy. And due to the lack of this specific promoter in normal cells, GAL-80 also has a normal inhibitory effect on GAL-4, so the loop is in an overall suppressed state.

We hope to construct a system which automatically sychronizes the circadian rhythms based on a key protein, pk2. The cell strain is supposed to produce a stable and continuous oscillation without the stimulus of any external cause.